Last reviewed · How we verify
I/N Midazolam
Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor, producing sedation, anxiolysis, and muscle relaxation.
Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor, producing sedation, anxiolysis, and muscle relaxation. Used for Sedation and anxiolysis prior to diagnostic and therapeutic procedures, Induction of general anesthesia, Acute anxiety and agitation.
At a glance
| Generic name | I/N Midazolam |
|---|---|
| Also known as | dormicum |
| Sponsor | Shaheed Zulfiqar Ali Bhutto Medical University |
| Drug class | Benzodiazepine |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia, Sedation, Anxiety |
| Phase | FDA-approved |
Mechanism of action
Midazolam binds to allosteric sites on GABA-A receptors in the central nervous system, increasing the frequency of chloride channel opening and hyperpolarizing neuronal membranes. This potentiation of GABAergic inhibition results in dose-dependent depression of the central nervous system, making it useful for sedation, anxiolysis, and anesthesia induction. The intravenous formulation (I/N refers to intravenous/intranasal administration) allows for rapid onset of action.
Approved indications
- Sedation and anxiolysis prior to diagnostic and therapeutic procedures
- Induction of general anesthesia
- Acute anxiety and agitation
- Seizure management (acute seizures)
Common side effects
- Respiratory depression
- Hypotension
- Drowsiness and sedation
- Headache
- Dizziness
- Amnesia
Key clinical trials
- A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity (PHASE1)
- A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer (PHASE1)
- Study of PBI-0451 in Healthy Subjects. (PHASE1)
- Effect of Aromatherapy on Perioperative Anxiety Level in Cesarean Sections (NA)
- Comparing the Efficacy of Intranasal Midazolam Versus Intravenous Diazepam for Control of Seizures in Children (PHASE4)
- Emergence Delirium in Children for Magnetic Resonance Imaging
- Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer (PHASE1)
- The Effects of Single-dose Rectal Midazolam Application on Post-operative Recovery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- I/N Midazolam CI brief — competitive landscape report
- I/N Midazolam updates RSS · CI watch RSS
- Shaheed Zulfiqar Ali Bhutto Medical University portfolio CI